Soluble ErbB3 and treatment of cancer

• US 7,745,398 B2
• Filed: 06/23/2008
• Issued: 06/29/2010
• Est. Priority Date: 05/31/2001
• Status: Active Grant

• Current Assignee: Tumor Biology Investment Group, Inc.
• Original Assignee: Tumor Biology Investment Group, Inc.
• Inventors: Maihle, Nita J., Lee, Hakjoo
• Primary Examiner(s): Woodward; Cherie M
• Application Number:
  US12/144,344
• Publication Number:
  US 20080267961A1
• Time in Patent Office: 736 Days
• Field of Search: None
• US Class Current: 514/19.3
• CPC Class Codes: A61K 38/179 for growth factors; for growth regulators
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: C07K 14/71 for growth factors; for growth regulators
• CPC Class Codes: C12N 15/1135 against oncogenes or tumor suppressor genes
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: G01N 2333/71 for growth factors; for growth regulators
• CPC Class Codes: G01N 2333/9121 with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
• CPC Class Codes: G01N 2800/50 Determining the risk of developing a disease
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 2800/54 Determining the risk of relapse
• CPC Class Codes: G01N 2800/56 Staging of a disease; Further complications associated with the disease
• CPC Class Codes: G01N 33/54306 Solid-phase reaction mechanisms
• CPC Class Codes: G01N 33/57407 Specifically defined cancers
• CPC Class Codes: G01N 33/57415 of breast
• CPC Class Codes: G01N 33/57434 of prostate
• CPC Class Codes: G01N 33/6872 Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Abstract

Regulation of sErbB3 isoforms in methods of regulating heregulin activity or ErbB receptor activities is disclosed. Cancer therapeutics and methods of therapeutically treating cancer comprising sErbB3 are also disclosed. Detection of sErbB3 in biological samples for risk assessment and prevention, screening, diagnosis, prognosis, theragnosis, evaluation of responsiveness to treatment, and/or monitoring of disease progression, recurrence, or metastasis of a cancer is disclosed as well. In examples, sErbB3 nucleic acid sequences, polypeptides, molecular probes, and antibodies are useful agents for regulation, expression, detection, and cancer therapeutics related to sErbB3.

Claims

1. A method for regulating heregulin activity, said method comprising administering an effective amount of an sErbB3 agent to a subject in need thereof, wherein the sErbB3 agent is a p85-sErbB3 or p45-sErbB3 polypeptide, and wherein the effective amount downregulates heregulin activity.

2. The method of claim 1 wherein said polypeptide consists of SEQ ID NO:

2 or SEQ ID NO;

4.